CollPlant Overview
CollPlant is a regenerative and aesthetic medicine company developing technologies and products for tissue regeneration and organ manufacturing. Its revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, CollPlant is developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.
Cumulative Funding Raised Over Time ($)
$4.5MApr 2007
$12.8MApr 2008
$14.8MFeb 2007
$15.8MFeb 2012
$20.3MFeb 2020
$55.3MFeb 2021
$58.9MMay 2025
$61.6MNov 2012
$69.0MNov 2017
$71.5MOct 2013
$73.0MSep 2006
$78.0MSep 2017
$83.5MSep 2019
Latest News
growth-positive
CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
CollPlant Biotechnologies has announced the expansion of its distribution network into North America through a new partnership with a U.S.-based logistics center. This move is aimed at enhancing the distribution of its rhCollagen and BioInk products in the U.S. and Canada. The logistics hub will provide cGMP-compliant storage and distribution services, ensuring efficient and secure product delivery. This expansion is expected to improve logistical efficiencies, reduce shipping times, and support CollPlants growing customer base. The company is committed to advancing regenerative medicine products and strengthening its presence in the North American market.
PartnersCustomers
growth-positive
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
CollPlant Biotechnologies announced positive results from a study comparing its rhCollagen-based bioink, Collink.3D™, with Matrigel®, a leading extracellular matrix. Conducted by the Levenberg Lab at Technion, the study found that Collink.3D™ outperformed Matrigel® in supporting structured tissue formation. Collink.3D™ demonstrated enhanced mechanical strength, elasticity, and stability, suggesting it could serve as a next-generation, animal-free extracellular matrix. This positions Collink.3D™ as a strong alternative for tissue engineering, regenerative medicine, and drug discovery applications. The global market for basement membrane matrices is projected to grow significantly, with CollPlants technology offering a sustainable and ethical approach.
Product Stage
growth-positive
A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D™, outperformed Matrigel®, a leading extracellular matrix,...
CollPlant Biotechnologies announced positive results from a study comparing its rhCollagen-based bioink, Collink.3D™, with Matrigel®, a leading extracellular matrix. Conducted by Technion, the study found that Collink.3D™ outperformed Matrigel® in supporting structured tissue formation, offering a consistent, tunable, and animal-free alternative for tissue engineering and research applications. CollPlants plant-based technology provides a sustainable and ethical approach without compromising performance. The company has a partnership with Allergan, an AbbVie company, for dermal and soft tissue fillers. Collink.3D™ is positioned as a next-generation bioink for regenerative medicine and drug discovery applications.
Partners
growth-positive
First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
CollPlant Biotechnologies, in collaboration with Mayo Clinic, has developed a fully humanized 3D bioprinted skin model using CollPlants plant-derived recombinant human collagen (rhCollagen). This innovative model serves as an alternative to animal testing for preclinical research, with applications in cosmetic and pharmaceutical testing, disease modeling, and drug development. The model integrates CollPlants rhCollagen-based bioinks with human skin cells, enabling high-throughput production of personalized human skin models and potential advancements in regenerative medicine. This development highlights the significant advantages of using rhCollagen in 3D bioprinting, offering a sustainable and ethical solution for various medical applications.
growth-positive
The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research. According to a scientific article published in the...
CollPlant Biotechnologies, in collaboration with Mayo Clinic, has developed a fully humanized 3D bioprinted skin model using its plant-derived recombinant human collagen (rhCollagen). This innovative model serves as an alternative to animal testing for preclinical research and has potential applications in cosmetic and pharmaceutical testing, disease modeling, and drug development. The collaboration highlights the advantages of using rhCollagen-based bioinks for high-throughput production of personalized human skin models, which could significantly impact regenerative medicine. CollPlants partnership with Mayo Clinic and its existing agreement with Allergan for dermal and soft tissue fillers further solidify its position in the regenerative and aesthetic medicine market.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $89.05M |
| Last funding | $3.6M |
| Stage | Mature |
| Rounds | 14 |
| Investors | 7 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | collplant.com |
Locations
Prof. Hillel ve-Khanan Oppenheimer St 4, Rehovot, Israel
Yesud HaMa'ala, Israel
Photos & Videos
5 item(s)
CollPlant Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsCore Technology
BiologicalsGenesMachinery & Robotics3D Printing & Additive ManufacturingTags (12)
orthopedicsregenerative-medicinebiomaterialstissue-regenerationpharmaceuticalstreatmentsmedical-devicesnanotechnology3d-technologydrug-deliverymedical-productsmedical-technologiesGeographic Markets
EuropeUnited StatesCollPlant Financials
$89.05M
Total funding
Undisclosed
Capital raised
$3.6M
Last funding
Mature
Funding stage
14
Total rounds
7
Investors
Cumulative Funding Raised Over Time ($)
$4.5MApr 2007
$12.8MApr 2008
$14.8MFeb 2007
$15.8MFeb 2012
$20.3MFeb 2020
$55.3MFeb 2021
$58.9MMay 2025
$61.6MNov 2012
$69.0MNov 2017
$71.5MOct 2013
$73.0MSep 2006
$78.0MSep 2017
$83.5MSep 2019
Private Equity Funding
PIPE
May 2025
$3.6M
Undisclosed Investor(s)
PIPE
Feb 2021
$35M
Undisclosed Investor(s)
PIPE
Feb 2020
$4.45M
Undisclosed Investor(s)
PIPE
Sep 2019
$5.5M
Undisclosed Investor(s)
PIPE
Nov 2017
$7.4M
Meitav Dash
PIPE
Sep 2017
$5M
Alpha Capital
Undisclosed Round
Oct 2013
$2.5M
Undisclosed Investor(s)
PIPE
Nov 2012
$2.8M
Yelin Lapidot Investment House, Meitav Dash
PIPE
Feb 2012
$1M
Biomedix, Docor International Management
Undisclosed Round
Apr 2008
$8.3M
Docor International Management
Undisclosed Round
Apr 2007
$4.5M
Docor International Management
Undisclosed Round
Feb 2007
$2M
Modgal Industries,
Undisclosed Round
Sep 2006
$1.5M
Public Offering / Exit
DelistingEvent
Oct 2018
Undisclosed
POEvent
Dec 2010
Undisclosed
ReverseMergerEvent
May 2010
Undisclosed
CollPlant Lifecycle
Cumulative Funding Raised Over Time
$4.5MApr 2007
$12.8MApr 2008
$14.8MFeb 2007
$15.8MFeb 2012
$20.3MFeb 2020
$55.3MFeb 2021
$58.9MMay 2025
$61.6MNov 2012
$69.0MNov 2017
$71.5MOct 2013
$73.0MSep 2006
$78.0MSep 2017
$83.5MSep 2019
All Events
PIPE
May 2025
$3.6M
Undisclosed Investor(s)
PIPE
Feb 2021
$35M
Undisclosed Investor(s)
PIPE
Feb 2020
$4.45M
Undisclosed Investor(s)
PIPE
Sep 2019
$5.5M
Undisclosed Investor(s)
PIPE
Nov 2017
$7.4M
Meitav Dash
PIPE
Sep 2017
$5M
Alpha Capital
Undisclosed Round
Oct 2013
$2.5M
Undisclosed Investor(s)
PIPE
Nov 2012
$2.8M
Yelin Lapidot Investment House, Meitav Dash
PIPE
Feb 2012
$1M
Biomedix, Docor International Management
Undisclosed Round
Apr 2008
$8.3M
Docor International Management
Undisclosed Round
Apr 2007
$4.5M
Docor International Management
Undisclosed Round
Feb 2007
$2M
Modgal Industries,
Undisclosed Round
Sep 2006
$1.5M
DelistingEvent
Oct 2018
Undisclosed
POEvent
Dec 2010
Undisclosed
ReverseMergerEvent
May 2010
Undisclosed
CollPlant News
138 articles
growth-positive
CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
CollPlant Biotechnologies has announced the expansion of its distribution network into North America through a new partnership with a U.S.-based logistics center. This move is aimed at enhancing the distribution of its rhCollagen and BioInk products in the U.S. and Canada. The logistics hub will provide cGMP-compliant storage and distribution services, ensuring efficient and secure product delivery. This expansion is expected to improve logistical efficiencies, reduce shipping times, and support CollPlants growing customer base. The company is committed to advancing regenerative medicine products and strengthening its presence in the North American market.
PartnersCustomers
growth-positive
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
CollPlant Biotechnologies announced positive results from a study comparing its rhCollagen-based bioink, Collink.3D™, with Matrigel®, a leading extracellular matrix. Conducted by the Levenberg Lab at Technion, the study found that Collink.3D™ outperformed Matrigel® in supporting structured tissue formation. Collink.3D™ demonstrated enhanced mechanical strength, elasticity, and stability, suggesting it could serve as a next-generation, animal-free extracellular matrix. This positions Collink.3D™ as a strong alternative for tissue engineering, regenerative medicine, and drug discovery applications. The global market for basement membrane matrices is projected to grow significantly, with CollPlants technology offering a sustainable and ethical approach.
Product Stage
growth-positive
A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D™, outperformed Matrigel®, a leading extracellular matrix,...
CollPlant Biotechnologies announced positive results from a study comparing its rhCollagen-based bioink, Collink.3D™, with Matrigel®, a leading extracellular matrix. Conducted by Technion, the study found that Collink.3D™ outperformed Matrigel® in supporting structured tissue formation, offering a consistent, tunable, and animal-free alternative for tissue engineering and research applications. CollPlants plant-based technology provides a sustainable and ethical approach without compromising performance. The company has a partnership with Allergan, an AbbVie company, for dermal and soft tissue fillers. Collink.3D™ is positioned as a next-generation bioink for regenerative medicine and drug discovery applications.
Partners
growth-positive
First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
CollPlant Biotechnologies, in collaboration with Mayo Clinic, has developed a fully humanized 3D bioprinted skin model using CollPlants plant-derived recombinant human collagen (rhCollagen). This innovative model serves as an alternative to animal testing for preclinical research, with applications in cosmetic and pharmaceutical testing, disease modeling, and drug development. The model integrates CollPlants rhCollagen-based bioinks with human skin cells, enabling high-throughput production of personalized human skin models and potential advancements in regenerative medicine. This development highlights the significant advantages of using rhCollagen in 3D bioprinting, offering a sustainable and ethical solution for various medical applications.
growth-positive
The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research. According to a scientific article published in the...
CollPlant Biotechnologies, in collaboration with Mayo Clinic, has developed a fully humanized 3D bioprinted skin model using its plant-derived recombinant human collagen (rhCollagen). This innovative model serves as an alternative to animal testing for preclinical research and has potential applications in cosmetic and pharmaceutical testing, disease modeling, and drug development. The collaboration highlights the advantages of using rhCollagen-based bioinks for high-throughput production of personalized human skin models, which could significantly impact regenerative medicine. CollPlants partnership with Mayo Clinic and its existing agreement with Allergan for dermal and soft tissue fillers further solidify its position in the regenerative and aesthetic medicine market.
Partners
growth-positive
One CollPlant Biotechnologies Insider Raised Their Stake In The Previous Year
The article discusses insider buying activity at CollPlant Biotechnologies Ltd., highlighting that insiders, particularly George Loewenbaum, have been net buyers of the companys stock over the past year. Loewenbaums significant purchase of shares suggests confidence in the companys future, despite it not having made a profit in the last twelve months. Insiders own about 31% of the company, equating to US$9.8 million worth of shares, indicating a strong alignment with shareholders. While the insider transactions are a positive sign, the article also notes caution due to the companys recent lack of profitability.
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based...
CollPlant Biotechnologies is advancing its photocurable dermal filler into clinical trials following positive results from its non-clinical program. The company is optimizing its manufacturing processes to prepare for these trials. The dermal filler, which combines hyaluronic acid with rhCollagen, offers immediate and long-lasting aesthetic benefits. CollPlants technology allows for precise contouring and tissue regeneration, marking a significant advancement in aesthetic medicine. The company has a partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers. CollPlant is focused on 3D bioprinting, tissue repair, and medical aesthetics, leveraging its proprietary plant-based genetic engineering technology.
Product StagePartners
growth-positive
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
CollPlant Biotechnologies is advancing its novel photocurable dermal filler into clinical trials following positive results from its non-clinical program. The filler, which combines hyaluronic acid with rhCollagen, offers immediate and long-lasting benefits for aesthetic medicine. The company is scaling and optimizing its manufacturing process to prepare for the upcoming clinical trials. This development marks a significant milestone for CollPlant as it aims to redefine the standard of care in aesthetic medicine with its proprietary technology. The company focuses on regenerative and aesthetic medicine, leveraging its plant-based genetic engineering technology to produce rhCollagen for various medical applications.
Product Stage
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and...
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, announced the expansion of its European distribution network for its Vergenix™ STR product through a new agreement with a distributor in Poland. Vergenix™ STR, based on CollPlants rhCollagen technology, is designed to promote healing and repair of tendon injuries. The product combines cross-linked rhCollagen with platelet-rich plasma to form a scaffold that supports localized and sustained therapeutic effects. CollPlants CEO, Yehiel Tal, expressed excitement about the market potential of Vergenix™ STR and plans to deliver the first shipment by the end of the year. The company is also focused on expanding its global distribution network.
growth-positive
CollPlant Expands the Distribution of its VergenixSTR Product in Europe
CollPlant Biotechnologies, a company specializing in regenerative and aesthetics medicine, has expanded its European distribution network for its Vergenix™ STR product by signing a new agreement with a distributor in Poland. Vergenix™ STR is designed to aid in the healing of tendon injuries by forming a scaffold that supports localized and sustained therapeutic effects. The expansion is part of CollPlants strategy to broaden its global distribution network, with the first shipment expected by the end of the year. The product leverages the companys rhCollagen technology and is intended for various tendon injuries, offering a differentiated treatment option.
Partners
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based...
CollPlant Biotechnologies, a leader in regenerative and aesthetic medicine, is set to participate in the International Conference on Biofabrication 2025. The company will present its innovative rhCollagen bioinks, which are pivotal for 3D bioprinting applications in tissue and organ engineering. CollPlants technology offers significant advantages, including biocompatibility and non-animal safety. The company has a strategic partnership with Allergan, an AbbVie company, for dermal and soft tissue fillers. This participation underscores CollPlants commitment to advancing biofabrication and highlights its role in the growing field of 3D bioprinting. The event will take place in Warsaw, Poland, from September 14-17, 2025.
Partners
growth-positive
CollPlant to Present at the 2025 International Conference on Biofabrication
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, is set to participate in the International Conference on Biofabrication 2025 in Warsaw, Poland. The company will present its advancements in 3D bioprinting using its proprietary rhCollagen technology. CollPlants presentations will focus on bioinks for biofabrication and computational modeling of biodegradable implants. The conference serves as a platform for discussing the latest research in biofabrication and bioprinting, attracting over 500 participants globally. CollPlants involvement highlights its role in advancing biofabrication technologies, particularly in tissue and organ engineering.
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based...
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, is set to participate in the 27th Annual H.C. Wainwright Global Investment Conference in September 2025. The company is known for its innovative use of non-animal-derived recombinant human collagen (rhCollagen) in 3D bioprinting, tissue repair, and medical aesthetics. CollPlant has a significant partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers. This participation in the conference is expected to enhance its visibility among investors and potentially foster new partnerships.
Partners
growth-positive
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference on September 8th and 9th, 2025. The company focuses on innovative medical solutions using its proprietary recombinant human collagen (rhCollagen) technology for 3D bioprinting, tissue repair, and aesthetics. CollPlant has a development and commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers. The conference participation is seen as a growth-positive move, potentially increasing visibility and investor interest.
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, is advancing its photocurable dermal filler program towards clinical trials and expanding its regenerative breast implant program. The company raised $3.6 million in a registered direct offering to support these initiatives. CollPlants partnership with AbbVie resulted in a $2 million milestone payment, and the company is expanding its distribution network for its tendon-repair product, Vergenix™ STR, in Europe and Asia. The company is also broadening its agreement with STEMCELL Technologies to include clinical development and commercial-scale manufacturing. CollPlant is making significant progress in developing non-animal-derived collagen solutions, positioning itself as a leader in the regenerative medicine market.
Product StageInvestmentPartnersExpand
growth-positive
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies, a company specializing in regenerative and aesthetics medicine, announced its financial results for the second quarter of 2025. The company is advancing its photocurable dermal filler program, which is in the final stages of preclinical testing, and preparing for clinical studies. CollPlant raised $3.6 million in a registered direct offering to support its initiatives. The company also received a $2 million milestone payment from its partner, AbbVie, for achieving a key development milestone. CollPlant has appointed a new Head of Commercial Operations for North America to expand distribution of its rhCollagen and bioink products. The company is focused on innovation and expansion in the medical aesthetics market.
InvestmentPartnersProduct StageExpandManagement Changes
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, announced it will report its financial results for the second quarter on August 20, 2025. The company focuses on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics using its proprietary rhCollagen technology. CollPlant has a development and global commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers. This partnership highlights CollPlants strategic collaborations in the medical aesthetics market.
Partners
growth-positive
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, announced it will report its financial results for the second quarter on August 20, 2025. The company focuses on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics using its proprietary rhCollagen technology. CollPlant has a development and global commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers. This partnership highlights CollPlants strategic collaborations in the medical aesthetics field.
Partners
growth-positive
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, has appointed Bowman Bagley as Vice President, Commercial North America. This strategic move aims to enhance the companys commercial strategy and market presence for its rhCollagen-based products in North America. Bagleys extensive experience in collagen-based biomaterials, 3D bioprinting, and tissue engineering aligns with CollPlants growth strategy. His role will involve leading sales, marketing, and logistics to expand the companys bioinks portfolio and rhCollagen sales. Bagleys appointment is expected to drive the companys commercial success and long-term value for shareholders.
Management ChangesExpand
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based...
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, has appointed Bowman Bagley as Vice President, Commercial North America. This new role is part of CollPlants strategy to expand its market presence and commercial operations in North America. Bagley brings extensive experience in collagen-based biomaterials, 3D bioprinting, and tissue engineering, aligning with CollPlants growth strategy. The company is focusing on scaling its rhCollagen product platforms and expanding sales in the research market and strategic collaborations. CollPlant has a partnership with Allergan, an AbbVie company, for dermal and soft tissue fillers. The appointment is seen as a positive step in accelerating the commercial success of CollPlants innovative product portfolio.
Management ChangesPartners
growth-positive
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
CollPlant Biotechnologies has expanded its agreement with STEMCELL Technologies to include the clinical development and commercial-scale manufacturing of its plant-derived recombinant human collagen (rhCollagen). This expansion marks a significant milestone for CollPlant, as it reflects the growing demand for safer and more sustainable alternatives to animal-sourced materials in the life sciences market. The partnership with STEMCELL Technologies, a leader in biotechnology, underscores the strength of CollPlants innovative technology and its commitment to advancing solutions in tissue regeneration and medical aesthetics. CollPlants rhCollagen is now set to play a crucial role in clinical and commercial applications, further solidifying its position in the regenerative medicine field.
Partners
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies has expanded its partnership with STEMCELL Technologies to include clinical development and commercial-scale manufacturing of its plant-derived rhCollagen. This expansion reflects the growing demand for safer, more effective, and sustainable solutions in the life sciences market. CollPlants rhCollagen is being positioned as a viable alternative to animal-sourced materials, aligning with industry priorities around safety and ethical sourcing. The partnership aims to advance research and biomanufacturing applications, highlighting CollPlants commitment to innovation in regenerative and aesthetic medicine. The collaboration with STEMCELL Technologies is expected to enhance CollPlants market presence and support its strategic goals.
Partners
growth-positive
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
CollPlant Biotechnologies has announced that the European Patent and Trademark Office has allowed a patent application related to its injectable fillers and regenerative breast implant candidates. This patent, effective until 2041, is a strategic move to expand the use of CollPlants rhCollagen technology into the growing markets of aesthetic and reconstructive procedures. The patent covers a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler. CollPlant aims to strengthen its market position in Europe, a key target market, by building protection around its proprietary technology. The company is developing a photocurable regenerative dermal and soft filler that offers several revolutionary effects and is intended for injection in a semiliquid phase.
Product Stage
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies has announced that the European Patent and Trademark Office has allowed a patent application related to its injectable fillers and regenerative breast implant candidates. This patent, effective until 2041, is part of CollPlants strategy to expand its rhCollagen technology into high-value markets such as injectable soft-tissue fillers and breast implants. The market for these products is significant, with the injectable fillers market estimated at over $6 billion and the breast implant market at over $3 billion. CollPlants technology aims to provide safer, regenerative solutions for aesthetic and reconstructive procedures. The company has a partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers.
Product StagePartners
growth-negative
Discover May 2025's Top Penny Stocks
CollPlant Biotechnologies Ltd., a company specializing in 3D bioprinting and medical aesthetics, is navigating the biotech sector with a market cap of $38.95 million. Despite reporting first-quarter sales of $2.06 million, the company remains unprofitable and pre-revenue in terms of significant income streams. It faces challenges such as high volatility and a limited cash runway of under one year if current cash flow trends persist. The company is seeking strategic partnerships to improve its financial position amidst ongoing industry developments, including FDA regulatory changes. The experienced management team and board are seen as crucial assets in this endeavor.
Product StagePartners
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies announced a registered direct offering and concurrent private placement to raise approximately $3.6 million. The company will issue 1,200,002 ordinary shares at $3.00 per share and warrants to purchase the same number of shares. H.C. Wainwright & Co. is the exclusive placement agent. The funds will support CollPlants partnership with AbbVie on a dermal filler product and other R&D programs. The offering is expected to close by June 2, 2025. CollPlant focuses on regenerative and aesthetic medicine using rhCollagen technology, with products in tissue repair and 3D bioprinting.
PIPEPartners
growth-positive
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
CollPlant Biotechnologies has announced a registered direct offering and a concurrent private placement to raise approximately $3.6 million. The company will issue 1,200,002 ordinary shares at $3.00 per share and warrants to purchase the same number of shares at the same price. The offering is expected to close by June 2, 2025. H.C. Wainwright & Co. is acting as the exclusive placement agent. The funds will be used for general corporate purposes, including supporting its partnership with AbbVie on a dermal filler product candidate and funding R&D programs.
PIPE
growth-positive
CollPlant Biotechnologies First Quarter 2025 Earnings: Misses Expectations
CollPlant Biotechnologies reported a significant improvement in its financial performance, with revenue increasing to US$2.06 million and net loss narrowing by 65% compared to the previous quarter. Despite missing analyst estimates for revenue and earnings per share, the companys shares have risen by 69% over the past week. Looking forward, CollPlants revenue is expected to grow at an average annual rate of 33% over the next three years, outpacing the US Biotech industrys forecasted growth rate of 17%. The article highlights potential risks, noting five warning signs for the company, two of which are significant.
growth-positive
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, announced its financial results for Q1 2025 and provided a corporate update. The company received a $2 million milestone payment from its partner, AbbVie, following a key development milestone in their collaboration on dermal and soft tissue filler products. CollPlant is advancing its regenerative breast implant program, which uses its proprietary rhCollagen technology, and is seeing promising preclinical results. The dermal filler candidate is currently in the clinical phase, with AbbVie reviewing interim results. CollPlant is focused on optimizing costs and pursuing non-dilutive transactions to support its growth.
Product StagePartnersInvestment
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, reported positive financial results for Q1 2025, driven by a $2 million milestone payment from AbbVie for advancements in their dermal filler program. The company is progressing with its regenerative breast implants and photocurable dermal filler, both in clinical stages. CollPlant is expanding its international distribution network for its Vergenix™ STR product and has secured new patents in Japan. Despite a 20% workforce reduction to optimize costs, the company remains focused on its core programs and aims to lead in regenerative medicine. The partnership with AbbVie and recent patent protections bolster CollPlants strategic position.
Product StagePartnersInvestmentLayoffsExpand
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, announced it will report its financial results for the first quarter on May 28, 2025. The company focuses on innovative technologies and products based on non-animal-derived rhCollagen for tissue regeneration and medical aesthetics. CollPlant has a significant partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers. This partnership highlights CollPlants strategic collaborations in the field of medical aesthetics and tissue repair.
Partners
growth-positive
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, is set to announce its financial results for the first quarter on May 28, 2025. The company focuses on innovative technologies like 3D bioprinting of tissues and organs, using its proprietary rhCollagen. CollPlant has a significant partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers. This partnership highlights CollPlants growth potential in the medical aesthetics market.
Partners
growth-negative
Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
CollPlant Biotechnologies is facing a challenging financial situation due to its high cash burn rate. As of December 2024, the company had $12 million in cash reserves but burned through $15 million in the past year, leaving it with a cash runway of only 10 months. This situation is concerning for shareholders, as the company does not yet generate significant operating revenue, reporting only $515,000 in the last twelve months. The company may need to raise additional funds through issuing new shares or taking on debt to sustain its operations. The rapid increase in cash burn, by 292% over the last year, further exacerbates the situation.
growth-positive
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
CollPlant Biotechnologies is leveraging its rhCollagen-based BioInk products to align with the FDAs recent initiative to phase out animal testing in drug development. The companys Collink.3D BioInks can be used in tissue-on-a-chip and organ-on-a-chip systems, providing alternatives to animal testing and potentially expediting the transition from benchtop studies to clinical trials. This development is expected to reduce costs and time to market for new therapies. CollPlant is also utilizing Computational Modeling and Simulation (CM&S) methodologies to advance its regenerative breast implant product, further reducing the need for animal studies. These innovations position CollPlant as a key player in the shift towards more human-relevant testing methods.
growth-positive
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven?
CollPlant Biotechnologies Ltd., a company specializing in 3D bioprinting of tissues and organs, is nearing a significant milestone in its business. The company, which operates in the US, Canada, Israel, Europe, and internationally, reported a loss of $17 million for the financial year ending December 31, 2024. However, analysts predict that CollPlant is on the verge of breaking even, with expectations of turning a profit of $1.1 million in 2026. The company is anticipated to grow at an average rate of 57% year-on-year to achieve this goal. Notably, CollPlant operates without debt, relying solely on shareholder funding, which reduces investment risk.
growth-positive
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
CollPlant Biotechnologies announced six-month study data from its regenerative breast implant program, targeting a $3 billion market. The company received a $2 million development payment from its partner AbbVie, under a collaboration agreement for dermal and soft tissue fillers using CollPlants rhCollagen technology. The dermal filler product is in the clinical phase, with AbbVie reviewing interim results. CollPlant also gained a U.S. patent for its dermal filler and expanded the distribution network for its Vergenix STR product. The company aims to optimize costs and maintain a strong cash position to support its growth strategy.
Product StagePartnersInvestment
growth-positive
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, will report its financial results for the fourth quarter and full year of 2024 on March 26, 2025. The company will host a conference call to discuss these results and provide corporate updates. CollPlant focuses on innovative technologies using non-animal-derived collagen for medical aesthetics and tissue regeneration. The company has a significant partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers. The announcement is expected to have a growth-positive impact on the company as it highlights its ongoing developments and partnerships.
Partners
growth-positive
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
CollPlant Biotechnologies has expanded its distribution channels for its VergenixSTR product in Europe and Asia. The company has signed new distribution agreements with companies in the Netherlands, Turkey, and India, targeting sales in Benelux, Spain, India, and Turkey. VergenixSTR, based on CollPlants rhCollagen technology, is designed to treat tendinopathy by promoting tendon healing. The product combines rhCollagen with Platelet-rich plasma to form a gel matrix that facilitates localized release of growth factors, enhancing the healing process. The first shipment to the new distributor in Benelux and Spain occurred in February 2025, while distributors in Turkey and India are finalizing regulatory processes to begin sales in 2025.
Partners
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and...
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, announced the expansion of its distribution channels for its Vergenix™ STR product in Europe and Asia. The product, based on rhCollagen technology, is designed to treat tendinopathy by promoting tendon healing. CollPlant has signed new distribution agreements with companies in the Netherlands, Turkey, and India, targeting sales in Benelux, Spain, India, and Turkey. The first shipment to the Benelux and Spain distributor occurred in February 2025. The expansion is expected to enhance the market potential for VergenixSTR, which offers a unique treatment for tendon injuries. CollPlants CEO, Yehiel Tal, expressed excitement about the market potential and plans to further expand the distribution network.
Partners
growth-positive
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and...
CollPlant Biotechnologies announced the granting of a U.S. patent for its photocurable dermal filler product candidate, which uses modified recombinant human collagen (rhCollagen). This strengthens its intellectual property in the U.S., a strategic market. CollPlant has a partnership with AbbVie, which has an exclusive license to use CollPlants rhCollagen technology for dermal and soft tissue fillers. AbbVie is conducting clinical trials, and a contingent payment of $2 million was triggered by the agreement. CollPlant is implementing cost reductions, including a 20% workforce reduction, to extend its cash runway until 2026. The company focuses on advancing its product pipeline, including a regenerative breast implant candidate.
Product StagePartnersCustomersLayoffs
growth-positive
CollPlant Biotechnologies Provides a Corporate Update
CollPlant Biotechnologies announced the granting of a U.S. patent for its photocurable dermal filler product candidate, which is based on modified recombinant human collagen. This patent strengthens CollPlants intellectual property in the U.S. market, a strategic target for the company. Under a development and commercialization agreement, CollPlant has licensed its rhCollagen technology to AbbVie for dermal and soft tissue fillers. AbbVie is conducting clinical trials and has made a $2 million contingent payment to CollPlant. The company plans cost reductions to extend its cash runway and will update on the clinical trials progress once concluded.
Product StagePartnersInvestment
growth-negative
US Penny Stocks To Watch In January 2025
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for solid tumors and other diseases. Despite being debt-free and having a sufficient cash runway for over a year, the company remains unprofitable with earnings forecasted to decline by 3.2% annually over the next three years. Recent strategic moves include a collaboration with Kuva Labs for advanced imaging agents and the completion of patient enrollment in its CENDIFOX trial. The company has experienced shareholder dilution but maintains financial stability with short-term assets covering liabilities. Lisatas market cap stands at $31.31 million, and it is currently a pre-revenue company.
Product StagePartners
growth-positive
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies has announced promising results from its pre-clinical study of rhCollagen-based regenerative breast implants, which show significant vascularization and rapid tissue ingrowth. The company is advancing towards human trials, targeting a $3 billion market opportunity. As of September 30, 2024, CollPlant reported a cash balance of $15.4 million and is focusing on raising non-dilutive cash through collaborations in the medical and aesthetics fields. The innovative technology aims to meet the unmet need for biocompatible materials in plastic surgery, potentially eliminating immune responses. The company plans to report further results in early 2025.
growth-positive
US Penny Stocks With Market Caps Under $3B
CollPlant Biotechnologies Ltd., a company specializing in regenerative and aesthetic medicine, is making strides in the 3D bioprinting sector. Despite being a pre-revenue company with less than $1 million in revenue, CollPlant has a strong financial position with no debt and a seasoned management team. The company has recently entered into strategic collaborations with Stratasys to develop innovative 3D bioprinting solutions for breast implants, targeting the $3 billion global breast implant market. With a market cap of $45.59 million, CollPlant is well-positioned for growth, maintaining a cash runway for over three years. The article highlights the companys potential in the growing field of 3D bioprinting and its robust financial health.
Partners
growth-positive
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, announced it will report its financial results for the third quarter of 2024 on November 27, 2024. The company will host a conference call and webcast to discuss these results and provide corporate updates. CollPlant focuses on 3D bioprinting and medical aesthetics using its proprietary rhCollagen technology. The company has a development and commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers. This announcement is likely to have a growth-positive impact on the company as it highlights its innovative technologies and strategic partnerships.
CustomersPartners
growth-negative
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In Growth
The article discusses the financial situation of CollPlant Biotechnologies, focusing on its cash burn rate and cash reserves. As of June 2024, the company reported having $19 million in cash and no debt, with a cash burn of $3.5 million over the past year, giving it a cash runway of 5.4 years. Despite a 76% reduction in cash burn, the company has not yet achieved significant operating revenue, reporting only $689,000 in the last twelve months. Analysts predict that CollPlant may reach cashflow breakeven before exhausting its cash reserves. The article highlights the potential need for the company to raise additional funds through issuing new shares or taking on debt to support future growth.
Growth-Positive
Even after rising 10% this past week, CollPlant Biotechnologies (NASDAQ:CLGN) shareholders are still down 71% over the past three years
CollPlant Biotechnologies Ltd.s share price has climbed by 10% this week, a positive sign after a three-year decline of 71%. The companys revenue has shrunk by 33% per year over the last three years, a trend that has been reflected in the share price. Despite the recent uptick, the companys financial health remains a concern, with the company not being profitable in the last twelve months. While the broader market gained around 28% in the last year, CollPlant Biotechnologies shareholders lost 21%.
growth-positive
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies has reported its financial results for Q2 2024, revealing a cash balance of $18.9 million as of June 30, 2024. The company has made significant progress in its regenerative breast implant program, launching a pre-clinical trial with 200cc commercial-sized breast implants printed with Stratasys Origin® 3D printer. The company also released its first ESG and Sustainability report, outlining its commitment to a sustainable future. CollPlants CEO, Yehiel Tal, stated that the companys overall strategy is driven by its vision to lead in regenerative medicine and improve global health with its innovative collagen technology.
InvestmentPartnersExpand
growth-positive
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
CollPlant Biotechnologies and Stratasys Ltd. have announced the initiation of a pre-clinical study for 200cc commercial-sized regenerative breast implants printed on a Stratasys Origin 3D printer. The study aims to test the ability of the implants to promote the growth of natural breast tissue and degrade over time. The implants are designed to regenerate an individuals natural breast tissue without eliciting an immune response. The collaboration between the two companies is focused on the development of a bioprinting solution for CollPlants breast implants and finding solutions to scale-up the implants fabrication process.
PartnersExpand
Neutral
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, has announced that it will report its financial statements for the second quarter of 2024 on August 20, 2024. The company will also host a conference call and webcast to discuss its financial statements and corporate updates. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company.
Partners
growth-positive
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has released its first Environmental, Social and Corporate Governance (ESG) and Sustainability Report. The report outlines the companys initiatives to adopt an ESG strategy, focusing on areas with the highest impact. The company plans to enhance plant-based production, reduce emissions, and deliver safe and reliable medical solutions. The report reflects CollPlants commitment to environmental sustainability, human health, and corporate governance. The companys strategy is based on three pillars: Impact on the Planet, Impact on People, and Impact on Business Conduct.
Partners
growth-positive
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant Biotechnologies has announced the successful printing of commercial-sized 200cc breast implants using its proprietary rhCollagen bioinks. The company also reported positive interim preclinical data from ongoing large-animal studies evaluating its regenerative breast implants. The implants are expected to regenerate breast tissue without eliciting an immune response, providing a potential alternative for aesthetic and reconstructive procedures. CollPlant has initiated an additional large-animal study to evaluate commercial-size versions of the 3D-bioprinted, regenerative breast implants, with results expected in Q4 2024 and Q1 2025.
InvestmentExpand
growth-positive
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant Biotechnologies has successfully printed commercial size breast implants of 200 cc using its proprietary rhCollagen bioinks. The company also announced positive interim preclinical data from ongoing large-animal studies evaluating its regenerative breast implants. The implants are expected to regenerate breast tissue without eliciting an immune response, providing a potential alternative for aesthetic and reconstructive procedures. CollPlant has initiated an additional large-animal study to evaluate commercial-size versions of the 3D-bioprinted, regenerative breast implants, with results expected in Q4 2024 and Q1 2025.
InvestmentExpand
growth-negative
CollPlant Biotechnologies First Quarter 2024 Earnings: Misses Expectations
CollPlant Biotechnologies reported a 77% decrease in revenue for Q1 2024, compared to Q1 2023. The company also reported a net loss of $4.20 million, a 13% increase from the previous year. Earnings per share also deteriorated, with a loss of $0.37 per share compared to a loss of $0.33 in Q1 2023. The companys shares are down 9.2% from a week ago. Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
CustomersPublic Trading
growth-negative
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has announced its financial results for the first quarter of 2024 and provided a corporate update. The company is currently conducting large-animal trials for its 3D bioprinted regenerative breast implants, with no commercially-available implants currently allowing for the regeneration of breast tissue. CollPlant has also been working on its first Environmental, Social and Governance (ESG) report. The companys GAAP revenues for Q1 2024 were $98,000, a decrease of $335,000 compared to Q1 2023. The companys cash and cash equivalents balance as of March 31, 2024 was $23.2 million.
Management ChangesInvestment
Neutral
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has announced that it will report its financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets. The company will then host a conference call and webcast to discuss its financial results and corporate updates. CollPlants products are based on its rhCollagen (recombinant human collagen) produced with CollPlants proprietary plant-based genetic engineering technology.
growth-positive
CollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its Business
The article discusses the financial health of CollPlant Biotechnologies, focusing on its cash burn rate. The companys cash burn is the annual rate at which it spends cash to fund its growth. The company had a cash runway of about 7.2 years from December 2023, which indicates that the company is in a good position to continue to fund its growth. The companys cash burn has reduced by 75% over the last twelve months, which is good for protecting the balance sheet. The company has a market capitalisation of US$60m and its cash burn equates to about 6.2% of its market value.
Investment
growth-positive
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has announced its financial results for the full year ended December 31, 2023. The company ended 2023 with $26.7 million in cash and cash equivalents. CollPlant has made significant progress with its development partner, AbbVie, to advance the dermal and soft tissue filler program toward commercialization. In June 2023, CollPlant announced the achievement of an important milestone under the AbbVie collaboration which triggered a $10 million payment from AbbVie to CollPlant. CollPlant also announced a joint development and commercialization agreement with Stratasys Ltd. to collaborate on the development of a solution to bio-fabricate human tissues and organs.
PartnersInvestment
Neutral
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, has announced it will report its financial results for 2023 on April 4, 2024. The company will also host a conference call and webcast to discuss these results and provide corporate updates. CollPlants products, based on its proprietary plant-based genetic engineering technology, are used in tissue repair, aesthetics, and organ manufacturing. In 2021, the company entered into a development and commercialization agreement with Allergan, an AbbVie company.
Partners
growth-negative
Shareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years ago
CollPlant Biotechnologies Ltd. has seen a significant drop in its share price over the last three years, with a decrease of 61%. Over the last year alone, the share price fell 40%. The companys revenue has also dropped 34% per year over the last three years. The company has not been profitable in the last twelve months, which, combined with falling revenue, has led to investors selling off the stock. The companys performance has been weaker than the market, which is up 32%.
Public Trading
growth-positive
CollPlant Issues Letter to Shareholders
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has made significant progress in 2023. The company has strengthened existing business collaborations and initiated new opportunities. It has made progress with its development partner, AbbVie, to advance its dermal and soft tissue filler toward commercialization. CollPlant has also announced a joint development and commercialization agreement with Stratasys Ltd. to collaborate on the development of a solution to bio-fabricate human tissues and organs. The company is also developing a bioprinted human intestine model for personalized treatment of ulcerative colitis.
PartnersExpand
growth-positive
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
CollPlant Biotechnologies CEO, Mr. Yehiel Tal, will participate in the Octane Aesthetic Tech Forum on January 25-26, 2024. He will present the companys 3D bioprinted regenerative breast implants in development, which are made from CollPlants proprietary rhCollagen and other proprietary biomaterials. These implants are expected to regenerate breast tissue without eliciting an immune response. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a global leader in the dermal filler market.
Partners
growth-positive
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has initiated a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. The companys implants are designed to regenerate breast tissue and have inherent safety advantages. The study aims to obtain data to optimize the implant design for a large-animal study intended to be discussed with the FDA. The implants are expected to provide a revolutionary alternative for aesthetic and reconstructive procedures, including postmastectomy for cancer patients. In 2021, CollPlant entered into a development and global commercialization agreement with Allergan, an AbbVie company.
InvestmentExpand
growth-positive
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has announced its financial results for the third quarter of 2023. The company received a $10 million milestone payment from its partner, AbbVie Inc., for achieving a major milestone in the second quarter. The company is also preparing to launch a large-animal study with a commercial size breast implant by the end of the year. The companys cash and cash equivalents totaled $29 million as of September 30, 2023, representing an estimated cash runway of at least two years. The companys revenues for the first nine months of 2023 were $10.7 million and operating loss was $2.4 million.
PartnersInvestment
Neutral
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, announced that it will report its financial results for the third quarter of 2023 on November 29, 2023. The company will host a conference call and webcast to discuss its financial results and corporate updates. CollPlants products are based on its rhCollagen produced with its proprietary plant-based genetic engineering technology. These products are used in tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company.
growth-negative
Will CollPlant Biotechnologies (NASDAQ:CLGN) Spend Its Cash Wisely?
CollPlant Biotechnologies, a biotech company, is under scrutiny due to its cash burn rate. The company had a cash runway of approximately 18 months as of June 2023, with cash of US$22m and no debt. However, its cash burn was US$15m over the trailing twelve months, indicating that the end of the cash runway is in sight unless cash burn reduces drastically. The companys cash burn increased by 4.2% over the last year, suggesting that management is increasing investment in future growth. The companys cash burn of US$15m is about 20% of its US$76m market capitalisation, indicating that it could raise more cash for growth but at the cost of diluting shareholders.
Investment
growth-positive
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
CollPlant Biotechnologies, a company specializing in regenerative and aesthetics medicine, has been granted a patent by the U.S. Patent and Trademark Office for its photocurable dermal filler product. The product, which is currently under development, is based on CollPlants non-animal-derived collagen technology. The patent is part of the companys strategy to expand into new markets, with the U.S. being a key target. The dermal filler is designed to enable tissue regeneration and contouring, and the patent provides coverage until 2039. In 2021, CollPlant entered into a development and global commercialization agreement with Allergan, an AbbVie company.
CustomersPartners
growth-negative
Shareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years ago
CollPlant Biotechnologies Ltd. has seen a decline in its share price by 27% over the last three years, underperforming the market return of about 21%. The companys revenue has also shrunk by 32% per year over the same period. The company has not been profitable in the last twelve months and its share price has further declined by 28% in the last quarter. The company needs to return to revenue growth to regain investor confidence.
Customers
growth-positive
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has joined the United Nations Global Compact, the worlds largest initiative for sustainable and responsible corporate governance. As a new member, CollPlant is committed to operating sustainably and producing sustainable alternatives to the regenerative and aesthetics medicine products and technologies that currently exist. The companys products are based on its non-animal-derived collagen for tissue regeneration and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement with Allergan, an AbbVie company.
Partners
growth-positive
CollPlant to Present at the H.C. Wainwright Annual Growth Conference
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, has announced its participation in the H.C Wainwright Annual Growth Conference to be held from September 11-13, 2023. The companys Deputy CEO and CFO, Eran Rotem, is scheduled to present at the conference. CollPlants products are based on its proprietary plant-based genetic engineering technology and address various fields including tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement with Allergan, a global leader in the dermal filler market.
Partners
growth-negative
Results: CollPlant Biotechnologies Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts
CollPlant Biotechnologies Ltd. has released its quarterly report, showing strong statutory earnings performance with revenue of US$10m, beating expectations by 98%, and earnings per share (EPS) of US$0.49, 513% ahead of expectations. However, analysts have cut their revenue estimates for next year and increased their loss per share forecasts. The consensus price target fell 35% to US$16.88. Despite the strong performance, the company is expected to grow slower than the wider industry.
Investment
growth-positive
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
CollPlant Biotechnologies announced its financial results for the second quarter of 2023, with revenues of $10.2 million. The company received a $10 million milestone payment from its partner, AbbVie, for achieving a major milestone in the clinical-phase dermal filler product. CollPlant also entered into a collaboration with Stratasys, a 3D printing company, to develop a bioprinting solution for the fabrication of CollPlants regenerative breast implants. The companys cash and cash equivalents totaled $22.3 million as of June 30, 2023.
InvestmentPartners
Neutral
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a company specializing in regenerative and aesthetics medicine, has announced that it will report its financial results for the second quarter of 2023 on August 24, 2023. The company will also host a conference call and webcast to discuss these results and provide corporate updates. CollPlants products, based on its proprietary non-animal-derived collagen, are used in tissue regeneration and organ manufacturing.
growth-positive
CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement
CollPlant Biotechnologies has announced the achievement of a milestone in its collaboration with AbbVie for the development of a regenerative dermal and soft tissue filler product. This milestone triggers a $10 million payment from AbbVie to CollPlant. The collaboration aims to create the first aesthetic product utilizing CollPlants non-animal-derived collagen technology. CollPlants CEO, Yehiel Tal, believes that the dermal filler under development could revolutionize the medical aesthetics field. The market for dermal fillers is estimated at $5.5 billion in annual sales with a projected 10% compounded annual growth rate. CollPlant has also received an upfront payment of $14 million and is eligible for additional milestone payments, royalty payments, and a fee for the manufacture and supply of rhCollagen.
Partners
growth-positive
CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has reported positive sales growth for its rhCollagen-based products and announced its Q1 2023 financial results. The company is also advancing its strategic collaboration with AbbVie to develop dermal and soft tissue filler products. CollPlant is preparing sites to begin a large-animal study in the second half of 2023 to advance its 3D bioprinted regenerative breast implant program. The company has also announced a collaborative agreement with Stratasys, a world leader in 3D printing, to utilize their proprietary 3D printer technology and combine it with CollPlants state-of-the-art rhCollagen-based bioinks.
CustomersPartnersExpand
growth-neutral
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies will report financial results for the first quarter of 2023 and host a conference call to discuss its financial results and corporate updates. The company is focused on regenerative and aesthetic medicine, particularly 3D bioprinting of tissues and organs. CollPlant has a development and commercialization agreement with Allergan for dermal and soft tissue fillers. The article does not mention any specific impact on the company or any partners, customers, or investment amounts. The event described in the article is scheduled for May 24, 2023.
InvestmentCustomers
growth-positive
ברחובות מפתחים מדפסת תלת-מימד לשתלי שד רגנרטיביים - Techtime - חדשות אלקטרוניקה והייטק
3D printer manufacturer Stratasys and biotech company CollPlant, both based in Rehovot Science Park, have announced a partnership to develop and commercialize a 3D printer for the industrial-scale production of regenerative breast implants. The development will be based on Stratasys P3 printer and CollPlants biological ink rhCollagen, which produces type 1 collagen, a key building block of tissues and organs in the human body. The partnership aligns with Stratasys strategy to provide full solutions for high-growth industrial applications.
PartnersExpand
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
growth-positive
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
Stratasys Ltd. and CollPlant Biotechnologies have announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs. The first project focuses on the development of an industrial-scale solution for CollPlants regenerative breast implants program. The new bioprinter, based on Stratasys’ precise P3 3D printing technology in combination with CollPlants flagship bioinks, will enable the production of CollPlant’s state of the art breast implants. Both companies have agreed to cross-promote each other’s bioprinting products.
PartnersExpand
Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update
growth-positive
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a regenerative and aesthetics medicine company, has announced that it will report its financial results for the full year ended December 31, 2022, on March 29, 2023. The company will host a conference call and webcast to discuss its financial results along with corporate updates. CollPlants products are based on its rhCollagen produced with its proprietary plant-based genetic engineering technology. In 2021, CollPlant entered into a development and global commercialization agreement with Allergan, an AbbVie company.
Investment
growth-positive
CollPlant Issues Letter to Shareholders
CollPlant, a regenerative and aesthetics medicine company, has reflected on its achievements throughout 2022 in a letter from its CEO, Yehiel Tal. The company leveraged its collagen-based platform to strengthen existing business collaborations and form new ones. It continued to develop products for regenerative and aesthetic medicine. The company made significant progress with its development partners, including a long-term collaboration with AbbVie. CollPlant also expanded into personalized medicine, signing a collaboration agreement with Tel Aviv University and Sheba Medical Center. The company plans to further advance and expand its portfolio of innovative products and partnerships in 2023.
PartnersExpand
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives
CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form
We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
growth-negative
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results
CollPlant Biotechnologies, a regenerative and aesthetic medicine company, has announced its financial results for Q3 2022. The company reported a net loss of $4.4 million for the quarter, compared to a net loss of $3.1 million for the same period in 2021. Despite the losses, the companys CEO, Yehiel Tal, highlighted the progress made in product development and partnerships, including a collaboration with AbbVie to develop a dermal and soft tissue filler and a partnership with Tel Aviv University and SHEBA Hospital to develop a 3D bioprinted model of the human intestine. The companys cash and cash equivalents stood at $33 million as of September 30, 2022.
PartnersManagement Changes
CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis
CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90
growth-positive
CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90
CollPlant is launching Collink.3D™ 90, a recombinant human collagen-based bioink for 3D bioprinting applications. The bioink offers increased mechanical properties for printing soft and hard tissues. It demonstrates faster human cell migration compared to a commercial hydrogel. CollPlant aims to provide a favorable alternative to existing commercial bioinks with its high bio-functionality, rheological properties, and high purity. The company sees bioinks as an important strategic platform for licensing and collaboration agreements. Collink.3D™ 90 has the potential to perform as a superior, animal-free, human cell culture substrate. The bioink is compatible with major 3D bioprinting technologies and cell types. CollPlant is focused on 3D bioprinting of tissues and organs, as well as medical aesthetics.
Customers
CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17
growth-positive
CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17
CollPlant Biotechnologies announced that its Deputy CEO and CFO will present a company overview at a forum. The company has entered into a development and global commercialization agreement with Allergan Aesthetics for dermal and soft tissue fillers. CollPlant is focused on 3D bioprinting of tissues and organs, as well as medical aesthetics. The companys products are based on its recombinant human collagen product with proprietary plant-based genetic engineering technology. The announcement highlights CollPlants involvement in regenerative and aesthetic medicine, particularly in the field of tissue repair, aesthetics, and organ manufacturing.
Partners
CollPlant to present at the Dawson James Small Cap Growth Conference on October 12
growth-positive
CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy
CollPlant, a regenerative and aesthetics medicine company, announced it will present on Recombinant Human Collagen-based Bioinks for Biofabrication and Modeling Applications at the International Conference on Biofabrication on September 28th. The company will also have an exhibition booth at the Conference from Sept 25th-28th. CollPlants products are based on its recombinant human collagen produced with its proprietary plant-based genetic engineering technology. The company has entered into partnerships with Allergan, an AbbVie company, and 3D Systems.
Partners
growth-positive
CollPlant Biotechnologies to Participate in September Investor Conferences
CollPlant Biotechnologies announced that its Deputy CEO and CFO will participate in investor conferences later this month. The company is focused on 3D bioprinting of tissues and organs, and medical aesthetics. CollPlant has entered into development and commercialization agreements with Allergan and 3D Systems for dermal and soft tissue fillers and a 3D bioprinted regenerative soft tissue matrix for breast reconstruction procedures. The companys products are based on its rhCollagen produced with proprietary plant-based genetic engineering technology. CollPlant aims to revolutionize regenerative and aesthetic medicine.
Investment
growth-positive
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results
CollPlant Biotechnologies, a regenerative and aesthetic medicine company, has released its financial results for Q2 2022 and provided updates on its business developments. The companys co-development of rhCollagen-based dermal fillers with AbbVie is progressing well. CollPlants 3D bioprinted regenerative breast implant program is on track to conclude a large animal study in Q4 2022. The company also reported a strong balance sheet with cash and cash equivalents of $36M as of June 30, 2022. CollPlants CEO, Yehiel Tal, expressed satisfaction with the companys execution and significant advances across its diverse product portfolio.
PartnersInvestment
growth-positive
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results
CollPlant Biotechnologies, a regenerative and aesthetic medicine company, has announced its financial results for Q2 2022. The company reported a strong balance sheet with cash and cash equivalents of $36M as of June 30, 2022. The companys co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing well. The companys 3D bioprinted regenerative breast implant program is also on track to conclude a large animal study in Q4. Additionally, the development of an aseptic process for the production of sterile rhCollagen is anticipated to be completed in Q4.
PartnersInvestment
Growth-Negative
We're Hopeful That CollPlant Biotechnologies (NASDAQ:CLGN) Will Use Its Cash Wisely
CollPlant Biotechnologies, a loss-making company, is attracting investors attention due to its cash burn situation. The company had zero debt and cash worth US$41m as of March 2022, with a cash burn of US$14m in the last year, giving it a cash runway of 3.0 years. However, the companys operating revenue has declined by 94% in the last year, which is a concern. The companys cash burn equates to about 15% of its market value of US$92m, suggesting it could raise more cash for growth but at the cost of share dilution.
Investment
growth-positive
CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada
CollPlant, a regenerative and aesthetics medicine company, will deliver two presentations and have an exhibition booth at the annual conference of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) in Toronto, Canada, on July 10-13, 2022. The presentations will demonstrate the unique properties of rhCollagen-based compositions, which are used in a wide variety of biomaterials for different regenerative medicine applications. The companys marketing and R&D team will interact with researchers, scientists, and clinicians from both academia and industry to showcase their products.
Partners
CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study
growth-positive
CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study
CollPlant has initiated a study in large animals for its 3D bioprinted regenerative breast implant program. The company aims to address the $2.8 billion global breast implant market with its revolutionary and potentially safer product. The study will evaluate adipose tissue regeneration, tissue integration, vascularization of the implant, implant degradation rate, and host tissue response. CollPlant plans to launch a second study with human-sized implants after the conclusion of this study, leading to human clinical trials. The companys regenerative breast implants are made of its proprietary plant-derived rhCollagen, which offers better bio-functionality, superior homogeneity, and improved safety compared to silicone implants. The implants are designed to degrade over time and promote natural tissue regeneration and integration with host tissue. CollPlant has successfully produced prototypes of 3D bioprinted implants and is now approaching an important milestone with the large animal study.
Customers
growth-positive
היינן החוקר שמשתמש בצמח הטבק כדי לבנות איברים להשתלה
CollPlant, an Israeli biotechnology company, has developed a method of producing human collagen from genetically engineered tobacco plants. This collagen is then used as a bio-ink for 3D printing of tissues and organs. The company has two products that have completed clinical trials and received European approvals, one for healing diabetic ulcers and the other for repairing damaged tendons. In addition, CollPlant has a partnership with Allergan for the development of an injectable product for wrinkles. The company also has two products in development for breast reconstruction, particularly after mastectomy.
InvestmentExpand
growth-positive
CollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors
CollPlant has announced the appointment of Hugh Evans to its Board of Directors. Evans brings extensive board, 3D printing technology, and investment experience to CollPlant. His appointment is seen as a positive growth move for the company. CollPlant is a regenerative and aesthetics medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The companys products are based on its proprietary plant-based genetic engineering technology. CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company.
Management Changes
growth-positive
CollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft Tissue Filler Products
CollPlant Biotechnologies has entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company. CollPlant will receive an upfront payment of $14 million and is entitled to receive up to an additional $89 million in milestone payments. The collaboration is expected to create a paradigm shift in the medical aesthetics field. CollPlants rhCollagen is non-immunogenic and non-allergenic, offering better tissue regeneration performance than animal-derived collagen. This agreement further validates CollPlants technology as the gold standard collagen for regenerative and aesthetic medicine.
Partners
growth-positive
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant BioSpace
CollPlant Biotechnologies and United Therapeutics have expanded their collaboration to include the 3D bioprinting of human kidneys. United Therapeutics exercised its option to cover a second organ, human kidneys, and paid CollPlant $3 million for the option exercise. The collaboration aims to help reduce global organ shortages and potentially save the lives of millions of patients on kidney waiting lists. CollPlants proprietary recombinant human collagen (rhCollagen) and BioInk technology will be combined with United Therapeutics regenerative medicine and organ manufacturing capabilities. The collaboration agreement also grants United Therapeutics an exclusive license to CollPlants technology for the production and use of rhCollagen-based BioInk for 3D bioprinting of human kidneys. The collaboration was initially focused on 3D bioprinting of lung transplants.
PartnersExpand
growth-positive
CollPlant Biotechnologies Presents on the Use of Novel, Plant-Derived, Recombinant Human Collagen for Anti-Aging Therapies at the Science of Aging Virtual Symposium 2020
CollPlant presented a corporate overview on the dynamics of cellular aging at the Science of Aging Virtual Symposium 2020. The company showcased its plant-derived collagen technology and highlighted its Skin Rejuvenation and Breast Implant product pipeline. Data presented at the symposium demonstrated the effectiveness of CollPlants collagen in enhancing cell proliferation. CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs.
PartnersExpand
growth-positive
CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS)
CollPlant has signed a distribution agreement for its Vergenix Flowable Gel product in six CIS countries. The company has received the first order amounting to hundreds of thousands of U.S. dollars. The distributor is a Swiss-headquartered pharmaceutical group of companies. The agreement is for a five-year period. The distribution agreement is expected to increase clinical use of Vergenix FG in new patient populations. CollPlants Vergenix FG is a wound-care product designed to treat acute and chronic hard-to-heal wounds. It has already received positive feedback in Europe for rapid recovery of chronic wounds. CollPlant is focused on regenerative and aesthetic medicine, with a portfolio that includes 3D bioprinting of tissues and organs.
Partners
growth-positive
CollPlant Biotechnologies Raising $4.45 Million in U.S. Private Placement
CollPlant, a regenerative and aesthetic medicine company, has entered into definitive agreements for a capital raise of up to $4.45 million. The funds will be used to continue developing treatment options through the companys recombinant human collagen technology platform. The offering is expected to close within seven business days.
Investment
growth-positive
CollPlant Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors
CollPlant has appointed Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of its Board of Directors. Dr. Pomerantz is a highly experienced clinician and board member in the life science industry. His appointment is expected to bolster CollPlants strategic partnerships and clinical development efforts for its recombinant human collagen (rhCollagen) technology platform. CollPlant aims to provide innovative treatment options in the field of regenerative and aesthetic medicine. Dr. Pomerantzs extensive knowledge and expertise will contribute to the companys mission. CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
Management Changes
growth-positive
CollPlant Launches New Corporate Website to Showcase Recent Developments in Core Business Segments
CollPlant has announced the launch of its updated corporate website, showcasing its growth in the fields of regenerative and aesthetic medicine. The new website features improved functionality and rich content focused on the companys core business segments: Medical Aesthetics and 3D Bioprinting. The website redesign aligns with CollPlants latest advancements in its business segments, including regenerative dermal fillers and 3D bioprinted breast implants. The website will be regularly updated with news and information about the companys activities. The launch of the website is expected to have a positive impact on the companys growth.
CustomersPartners
growth-positive
3D Systems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine
3D Systems and CollPlant have signed a joint development agreement to advance breakthroughs in the biomedical industry. The collaboration aims to develop tissue and scaffold bioprinting processes for third-party collaborators. The companies will use a combination of 3D Systems printers, CollPlants BioInks, and new formulations of rhCollagen-based BioInks for their own products and deployments with third parties. The partnership is expected to have a positive impact on 3D Systems growth in the field of regenerative medicine. The article does not mention any specific customers, acquisition or investment amounts, layoffs, or management changes. The date of the event described in the article is January 13, 2020. Confidence level: 9.
Partners
growth-positive
CollPlant Partners in the Advanced Regenerative Manufacturing Institute
CollPlant has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private ManufacturingUSA initiative. ARMI aims to develop next-generation manufacturing processes and technologies for cells, tissues, and organs. The initiative is supported by over 150 partner organizations from industry, government, academia, and the non-profit sector. CollPlants BioInk, based on rhCollagen, is seen as an ideal building block for tissue and organ manufacturing. The collaboration with ARMI and its network of partners will contribute to the advancement of 3D bioprinting and next-generation manufacturing. CollPlant is honored to be part of this network of industry leaders.
PartnersInvestment
growth-positive
CollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication's Industry Relations Committee
CollPlants CEO was appointed to the Industry Relations Committee of ISBF. The committee aims to advance the biofabrication industry and promote collaboration between academia, industry, and regulatory agencies. CollPlant also presented a poster on their rhCollagen technology at the International Conference on Biofabrication. The company focuses on 3D bioprinting of tissues and organs and has a licensing agreement with United Therapeutics for the manufacture of 3D bioprinted lungs. The appointment of the CEO to the committee and the presentation at the conference indicate growth-positive impact on the company.
PartnersCustomers
https://www.pharmiweb.com/press-release/2019-09-03/collplant-biotechnologies-raising-55-million
growth-positive
CollPlant is Developing 3D-bioprinted Implants for Regeneration of Breast Tissue
CollPlant, a regenerative medicine company, is developing 3D bioprinted implants for breast tissue regeneration. The implants are made of CollPlants proprietary type I recombinant human collagen and additional materials, and are intended to promote breast tissue regeneration. The company believes that its technology can provide a revolutionary alternative to permanent breast implants, eliminating the high risk for adverse events. CollPlants technology has already attracted interest from leading companies in the segment. The companys products are based on its rhCollagen, produced with its proprietary plant-based genetic engineering technology. CollPlants flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. Last year, CollPlant entered into a licensing agreement with United Therapeutics for the use of its BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.
PartnersCustomers
growth-positive
Office Tour: CollPlant Offices - Rehovot
Setter Architects designed the nature-inspired offices of CollPlant, a medical company based in Israel. The design concept drew inspiration from the companys content world and reflected its plant-derived medical solutions. The offices were divided into two areas, with offices and shared workspace on one side and labs and development rooms on the other side. The design featured clean and elegant materials, natural lighting, and integrated plantings to create a sense of the exterior. The cafeteria was designed as a kitchenette and meeting area, with natural materials and plants. The project was completed by Setter Architects, with Sian Kapan as the head designer.
Customers
growth-positive
CollPlant Opens New Israeli R&D Center
Collplant Holdings Ltd. has relocated its headquarters and opened a new research and development center in Israel. The new facilities will support the companys development of its product pipeline for 3D bioprinting and dermal fillers. Collplant develops and manufactures collagen-based regenerative medical treatments and biological ink for the 3D printing of tissues and organs. In 2018, CollPlant signed a commercialization agreement with United Therapeutics Corp. to use CollPlants collagen-based bio-ink for the 3D printing of lung scaffolds.
PartnersExpand
growth-positive
CollPlant Announces Publication of Study in Science Translational Medicine Showing Composite Matrix Based on rhCollagen, Ceramics and Bone Morphogenic Protein Led to Bone Growth Superior to Standard of Care
CollPlant, a regenerative medicine company, has announced the publication of a study that demonstrates the superior efficacy and safety of a new bone repair treatment. The study, led by Bioventus, utilized a receptor optimized chimera version of BMP-2/BMP-6/activin A delivered in a composite matrix formulated with CollPlants rhCollagen and ceramic granules. The treatment showed superior bone formation at significantly lower concentrations of BMP compared to the standard dosage approved by the FDA. CollPlants CEO, Yehiel Tal, expressed satisfaction with the study results and highlighted the potential for the treatment to be used in a broader range of patients. CollPlant focuses on 3D bioprinting of tissues and organs, medical aesthetics, and tissue repair products for orthobiologics and advanced wound care markets.
PartnersCustomers
growth-positive
CollPlant Renews Distribution Agreement for Its Soft Tissue Repair Product Vergenix™STR With Arthrex a World Leader in Orthopedics
CollPlant has renewed its exclusive distribution agreement with Arthrex for Vergenix™STR, a regenerative medicine product for the treatment of tendinopathy. The agreement is extended through December 31, 2020, with Arthrex serving as the exclusive distributor in Europe, the Middle East, India, and certain African countries. The product, which combines bioengineered collagen with platelet-rich plasma, has shown positive results in a recent clinical trial. CollPlant plans to expand the distribution of Vergenix™STR to other territories, including Asia. Arthrex is a leading orthopedic products company.
Partners
growth-positive
Study Published in Wounds Journal Shows Remarkable Wound Closure Performance With CollPlant's VergenixFG in the Treatment of Chronic Wounds With a 94% Median Wound Area Reduction Within 4-weeks
CollPlant, a regenerative medicine company, has announced the results of a clinical study conducted with its VergenixFG wound care product. The study, published in the peer-reviewed journal Wounds, showed that the product yielded remarkable wound closure results in patients with chronic lower limb ulcers. Out of the twenty patients enrolled in the trial, nine wounds closed completely, fifteen wounds exhibited a greater than 70% closure, and the median wound area reduction was 94%. The study also reported a 50% reduction in pain for all patients. CollPlants VergenixFG is a flowable wound-filler made from genetically engineered plants and is commercially available in Europe. The company plans to expand its market presence to other markets.
Customers
growth-positive
CollPlant Announces Approval of Its rhCollagen Manufacturing Facility by European Union Notified Body
CollPlant, a regenerative medicine company, has received DEKRA Certification for its production facility in Rehovot, Israel. The certification allows CollPlant to produce and supply its recombinant human collagen, rhCollagen, for various applications including organ manufacturing and dermal fillers. The facility is also used for the production of CollPlants proprietary products. The 6,000 square foot facility includes clean rooms, logistics support areas, and dedicated production equipment. CollPlant is focused on 3D bioprinting of tissues and organs, medical aesthetics, and tissue repair products. The companys rhCollagen BioInk is being used by United Therapeutics for the manufacture of 3D bioprinted lungs. CollPlants Vergenix line of rhCollagen products includes a soft tissue repair matrix and a wound repair matrix.
Partners
growth-positive
CollPlant Announces Appointment of Jonathan M.N. Rigby as Chairman of the Board
CollPlant has appointed Jonathan M.N. Rigby as Chairman of the Board of Directors. Rigby brings extensive industry experience and leadership skills to the company. His appointment is expected to help CollPlant achieve its goals and realize the potential of its platform technology. Rigby has a successful track record in growing and capitalizing specialty pharmaceutical companies. CollPlant recently entered into a licensing agreement with United Therapeutics, which is using CollPlants BioInks in the manufacture of 3D bioprinted lungs for transplant in humans. CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, medical aesthetics, and developing tissue repair products.
Management Changes
growth-positive
Clinical Trial Published in the Journal of Shoulder and Elbow Surgery Concludes That CollPlant's Vergenix™ STR Effectively Demonstrates Significant Clinical Improvements in Tennis Elbow
CollPlant, a regenerative medicine company, announced positive results from a clinical trial of its Vergenix™STR treatment for tennis elbow. The trial showed a 59% improvement in a key measure of tennis elbow at 6 months after treatment. CollPlant plans to pursue FDA regulatory approval for Vergenix™STR in the U.S. The treatment, which combines a collagen scaffold with autologous platelet-rich plasma, offers a unique and effective method for treating tendinopathies. CollPlant currently sells Vergenix™STR in Europe and has a CE mark. The company intends to conduct a pre-submission meeting with the FDA in the coming weeks. The U.S. market for tendinopathy procedures is estimated to be over 3 million annually.
Customers
growth-positive
CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
CollPlant has closed a worldwide exclusive license, development, and commercialization agreement with United Therapeutics Corporation for 3D bioprinted lung transplants. The agreement grants United Therapeutics an exclusive license to CollPlants technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants. CollPlant will manufacture and supply BioInk for a few years and provide technical support to United Therapeutics. The agreement also includes an option for United Therapeutics to expand the field of its license to add up to three additional organs. This partnership is expected to contribute to the growth and success of CollPlant in the field of 3D bioprinting and regenerative medicine.
PartnersExpand
growth-positive
3D bioprinted lungs to be available for global transplants
CollPlant, an Israeli regenerative medicine company, has signed a license, development, and commercialization agreement with United Therapeutics Corporation for 3D bioprinted lung transplants. The agreement combines CollPlants proprietary technology with United Therapeutics regenerative medicine capabilities. CollPlant will manufacture and supply BioInk for a few years and provide technical support to United Therapeutics. The agreement also grants United Therapeutics an option to expand the license to include three additional organs. Once approved, CollPlant will receive an upfront payment of $5 million and milestone payments of up to $15 million. The agreement is expected to have a positive impact on CollPlants growth.
PartnersInvestment
growth-negative
CollPlant Shares Will Be Traded From Tuesday Oct 30 Exclusively on Nasdaq
CollPlant, a regenerative medicine company, announced that its ordinary shares and warrants will no longer trade on the Tel-Aviv Stock Exchange (TASE) and will migrate exclusively to the Nasdaq Capital Market in the US. The company urges shareholders to convert their ordinary shares into American Depositary Shares (ADSs). The Bank of New York Mellon, the Depositary of the ADS program, will waive conversion and issuance fees until November 4, 2018. After that date, each conversion will be charged $0.05 per ADS. CollPlant focuses on 3D bioprinting of tissues and organs and develops tissue repair products for orthobiologics and advanced wound care markets. Its products are based on its proprietary plant-based rhCollagen technology.
Public Trading
growth-positive
Collplant soars on pact with United Therapeutics
CollPlant Holdings Ltd. has entered into a strategic collaboration agreement with United Therapeutics Corporation. United Therapeutics will use Collplants biological ink in its project to produce 3D bioprinted lung transplants. The agreement includes upfront and milestone payments to Collplant, as well as royalties on sales of commercialized products. CollPlant will grant United Therapeutics exclusivity in lung transplants. Trading in Collplant stock was temporarily suspended and then resumed with a 38% increase in share price. The stock will be delisted from the Tel Aviv Stock Exchange and continue to be traded on Nasdaq. The collaboration is seen as a major achievement for CollPlant and validates their technology.
PartnersInvestment
growth-positive
CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
CollPlant and United Therapeutics have entered into a license, development, and commercialization agreement for 3D bioprinted lung transplants. CollPlant will provide its proprietary technology and supply BioInk for the production of rhCollagen-based BioInk. United Therapeutics has the option to expand the license to include up to three additional organs. The agreement includes upfront and milestone payments for CollPlant, as well as royalties on sales of commercialized products. The collaboration aims to address the shortage of transplantable organs. The agreement is subject to closing conditions and approval by the Israel Innovation Authority.
Partners
Neutral
Dual-Listed CollPlant to Voluntarily Delist From Tel Aviv Stock Exchange
Regenerative medicine company CollPlant has announced that it will voluntarily delist its ordinary shares and Series I and K Warrants from the TASE. The last trading day on the TASE will be 29 October 2018. The companys American Depositary Shares will continue to trade on the Nasdaq Capital Market. The company is encouraging all holders of ordinary shares to convert their shares into American Depositary Shares through their banks or brokers. The Bank of New York Mellon, the Depositary of CollPlants ADS program, will waive its conversion and issuance fees for all shareholders who convert their ordinary shares until 4 November 2018.
Public Trading
growth-positive
CollPlant Opens a New rhCollagen Production Facility
CollPlant, a regenerative medicine company, has announced the opening of a new rhCollagen production facility in Israel. The facility will enable operational flexibility and cost reduction for the companys rhCollagen and end products, enhancing competitiveness and profitability. The facility will also serve for process development of new production technologies. The first production runs have been successfully completed, and validation is expected to take place in the second quarter of 2018.
Expand
growth-positive
CollPlant Joins ReMDO's Advanced Biomanufacturing Initiative for Development of a Universal BioInk for 3D Bioprinting of Tissues and Organs
CollPlant has announced its participation in ReMDOs advanced biomanufacturing initiative for the development of a universal BioInk for 3D bioprinting of tissues and organs. ReMDO is leading the initiative with 18 research and industry organizations. CollPlants CEO believes that this collaboration validates the companys technology and positions its rhCollagen as the gold standard platform technology for collagen-based products. The article highlights CollPlants expertise in regenerative medicine and its focus on 3D bioprinting of tissues and organs. The companys flagship product, rhCollagen BioInk, is ideal for 3D bioprinting. ReMDO is a non-profit organization that aims to accelerate the discovery and translation of regenerative medicine therapies. The article includes forward-looking statements and mentions CollPlants recent registration statement with the SEC.
Partners
growth-positive
Tissue Regeneration Company CollPlant is Coming to Nasdaq
Tissue regeneration company CollPlant Holdings Ltd. is set to list on Nasdaq under the ticker CLGN. The company, which develops and manufactures collagen-based regenerative medical treatments and bio-ink used in 3D printing of tissues and organs, will not be raising funds as part of the listing. CollPlant previously secured a $5 million private investment agreement with Alpha Capital Anstalt, and as part of the agreement, it agreed to list on Nasdaq. The listing is expected to increase the companys global exposure and facilitate collaborations.
Public Trading
growth-positive
Regenerative medicine co CollPlant raises $7.4m
Israeli regenerative medicine company CollPlant Holdings Ltd. has raised a total of $7.4 million in investments. The investments include a private restricted investment agreement with Meitav-Dash and Ami Sagi, two of the companys largest shareholders. CollPlant is developing a 3D-printed orthopaedic implant and has received a first order for its collagen bio-ink for vital organ printing. The companys share price has risen 12.7% and is up 10% since the start of 2017.
Investment
growth-positive
$5 million funding regenerates CollPlant's 3D printed organ development plans
CollPlant, an Israeli regenerative medical materials developer, has received a $5 million investment from US venture capital firm Alpha Capital. This investment will support CollPlants long-term project of developing 3D printed transplantable organs. CollPlant has already established a division dedicated to 3D printing and filed a US patent for its 3D printable bio-ink. The company uses its own technology, rhCollagen, to bio-print human tissue. The investment is expected to accelerate the production of 3D printed bio-ink and make 3D printed organs for transplants available sooner. CollPlant has also announced a partnership with a leading medical devices company to develop an orthopedic implant prototype using its bio-ink. The company is looking to up-list to the NASDAQ Exchange.
InvestmentExpandPublic Trading
growth-positive
CollPlant raises $5m, to uplist on Nasdaq
CollPlant Holdings Ltd. plans to uplist its shares to the main Nasdaq exchange after raising $5 million from a US investor. The investors name has not been disclosed but will be revealed soon. The investment will enable CollPlant to uplist its shares on Nasdaq and potentially delist from the Tel Aviv Stock Exchange. CollPlant has two products approved for marketing in Europe but has not generated significant revenue from them yet. The company is also involved in 3D biological printing of tissues and organs. CollPlant is in talks with a party interested in making a substantial additional investment in the company.
InvestmentPublic Trading
growth-positive
CollPlant's New BioInk May Transform Transplant Medicine
CollPlant Ltd has introduced a new BioInk for 3D printing of tissues and organs. The BioInk is formulated from plant-extracted Type I rhCollagen and has shown excellent support for cell survival and proliferation. CollPlant is working with leading institutes and companies worldwide to implement the BioInk in various indications.
PartnersCustomers
growth-positive
CollPlant reports commercialization underway
CollPlant Holdings Ltd. has supplied its CE Mark-approved treatment for tendinopathy, VergenixSTR, to Arthrex GMBH. The company has also reported on the development of its collagen-based biological ink, bioInk, for use in 3D printing of organs and tissues. CollPlant reported a loss of NIS 27.9 million for 2016 and revenue of NIS 292 thousand.
CustomersPartners
growth-positive
Trial result boosts CollPlant
CollPlant, an Israeli collagen products company, announced positive final results of a trial for its wound treatment gel, Vergenix FG. The trial demonstrated that Vergenix FG is safe and efficacious in use on humans, with 70% to 100% closure of the wound observed in fifteen of the twenty patients treated. The company has submitted its CE Technical File to obtain CE Marking for Vergenix FG, targeting a market estimated at $5 billion. CollPlant is currently setting up the infrastructure for sales in Europe.
Customers
growth-positive
Tissue repair co Collplant jumps on US agreement
Israeli regenerative medicine company CollPlant Holdings Ltd. has signed an agreement with a leading US company in the field of orthobiologics for the development and potential commercialization of a novel absorbable bio-active surgical matrix for spinal fusion and trauma applications. The companys share price rose as a result of the agreement. The matrix is composed of CollPlants Type 1 recombinant human collagen and synthetic minerals. CollPlant estimates the worldwide target market for relevant spinal and trauma treatments to be $3.5 billion per annum.
Partners
CollPlant Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 62 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
CollPlant Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513578260 |
| Crunchbase | collplant |
| Phone | +972732325600 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-09T00:00:00.000Z |
| Created | 2014-07-24T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Dec, 2010; |